Top Markets
#1 Pleasing Gold Pleasing Gold +1,512.90%
#2 PulseChain PulseChain +58.12%
#3 Merlin's Seal BTC Merlin's Seal BTC +33.69%
#4 BOOK OF MEME BOOK OF MEME +31.60%
#5 Ontology Gas Ontology Gas +31.47%
#6 ConstitutionDAO ConstitutionDAO +25.51%
#7 Neiro Neiro +24.33%
#8 Unit Pump Unit Pump +22.47%
#9 Pump.fun Pump.fun +22.47%
#10 Collect on Fanable Collect on Fanable +21.07%
Coin of the day
Pleasing Gold Pleasing Gold
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
InnoPharmax Inc. InnoPharmax Inc.

InnoPharmax Inc.

4172
Classifica tra le azioni #26286
InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan,... InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan, operates as a specialized pharmaceutical enterprise. The company's core activities revolve around the development and market introduction of therapeutic products, with a particular focus on oncology and various other specialized medical fields within the Taiwanese market. Their current commercial portfolio encompasses N11005, an oral insulin designed for administration with meals, alongside GemOral. They also provide an Imipenem and Cilastatin solution, utilized for treating a broad spectrum of bacterial infections affecting areas such as the lower respiratory tract, skin and soft tissue, internal abdominal organs, gynecological systems, and bone and joints. Furthermore, InnoPharmax offers contrast agents, specifically gadopentetate dimeglumine and gadodiamide; oncology medications like Innomustine and Immurin; and Inpheno tablets, which are indicated for rare diseases. The company also provides advanced technology platforms, including the MUCR system, OralPas, and OralPas Pro. Looking at its research and development pipeline, InnoPharmax has several promising candidates. D07001 is currently in Phase I clinical trials for tumor treatment. C08001 has progressed to Phase III, targeting hypertension, heart failure, and left ventricular dysfunction following a myocardial infarction. Additional compounds in pilot bioequivalence (BE) trials include D07002, a potential supplement for phenylketonuria; C07001 for the management of Parkinson's disease; and N11001, which is being investigated for urological applications. The company is also actively formulating new contrast agents, D0131502 and D0051301.
Prezzo delle azioni
$0.35614911
Capitalizzazione di mercato
$41.95M
Variazione (1 giorno)
0.45%
Variazione (1 anno)
-50.84%
Paese
TW
Scambia InnoPharmax Inc. (4172)

Categoria

Healthcare
Utile per InnoPharmax Inc. (4172)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di InnoPharmax Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di InnoPharmax Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN